Brown: Risk Weighti...
Health Care: Drugs
Durect Corporation (DRRX: NASDAQ)
$0.89 -0.09 | -9.08%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 16.20M | -18.76M | -22.90M | -30.29M |
| Operating Gains/Losses | 0.00 | 8.00K | 74.00K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 1.28M | 268.00K | -2.02M | 2.36M |
| (Increase) Decrease in Inventories | -353.00K | -670.00K | -303.00K | 190.00K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 511.00K | 293.00K | -38.00K | 1.00K |
| (Decrease) Increase In Other Current Liabilities | -800.00K | -2.21M | 3.36M | -8.30M |
| (Increase) Decrease In Other Working Capital | -35.32M | -5.47M | 20.68M | 0.00 |
| Other Non-Cash Items | 4.44M | 6.88M | 8.05M | 12.30M |
| Net Cash From Continuing Operations | -13.45M | -17.39M | 7.76M | -20.89M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -13.45M | -17.39M | 7.76M | -20.89M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 29.35M | 47.52M | 61.28M | 36.80M |
| Purchases of Property, Plant & Equipment | -290.00K | -2.47M | -256.00K | -294.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -25.16M | -30.32M | -67.15M | -46.89M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 3.91M | 14.73M | -6.13M | -10.38M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 11.85M | 1.13M | 565.00K | 10.40M |
| Repayment of Long-Term Debt | -8.00K | -15.00K | -48.00K | -43.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | -240.00K |
| Net Cash From Financing Activities | 11.84M | 1.11M | 517.00K | 10.12M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 2.30M | -1.54M | 2.15M | -21.16M |
Portfolios with DRRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ProRobert Bruce
- Userdonellisor
- UserTrading
- Userbaustin002 Portfolio 1
- UserBarron's Research Reports 1...
Latest DRRX Headlines from TheStreet
- Durect Corporation Stock Downgraded (DRRX) 05.07.13 | 05:05 am
- 4 Stocks Under $5 Moving Higher 03.19.13 | 03:03 pm
- 4 Stocks Under $5 Making Big Moves 02.26.13 | 02:02 pm
- 5 Stocks Setting Up to Break Out 01.25.13 | 01:01 pm
- 8 Stocks Under $10 Making Big Moves 08.30.12 | 02:08 pm
- Durect Corporation Stock Upgraded (DRRX) 07.24.12 | 05:07 am
- Alkermes Needs to Build on Drug Delivery Success 06.18.12 | 07:06 am
- Business Highlights 06.24.11 | 06:06 pm
- Durect Stock Gaps Down On Today's Open (DRRX) 06.24.11 | 09:06 am
- Pfizer, Pain Therapeutics Drug Rejected by FDA 06.24.11 | 08:06 am
Press Releases for DRRX
- DURECT Announces Submission Of New Drug Application For POSIDUR⿢ (SABER®-Bupivacaine) - PR Newswire 04.16.13 | 07:04 am
- DURECT Corporation Invites You To Join Its Fourth Quarter 2012 Earnings Conference Call - PR Newswire 02.22.13 | 08:02 am
- DURECT To Participate In Upcoming Healthcare Conferences - PR Newswire 02.05.13 | 08:02 am
- DURECT Announces Positive Results From Reldayâ¿¢ Phase 1 Clinical Trial - PR Newswire 01.03.13 | 07:01 am
- DURECT Announces Pricing Of Public Offering Of Common Stock - PR Newswire 12.06.12 | 07:12 am
- DURECT To Participate In Upcoming Healthcare Conferences - PR Newswire 11.13.12 | 09:11 am
- DURECT Corporation Invites You To Join Its Third Quarter 2012 Earnings Conference Call - PR Newswire 10.30.12 | 04:10 pm
- DURECT To Participate In Upcoming Healthcare Conferences - PR Newswire 08.21.12 | 08:08 am
- DURECT Announces Intent To Submit NDA For POSIDUR⢠For Post-Operative Analgesia - PR Newswire 08.06.12 | 04:08 pm
- DURECT Corporation Invites You To Join Its Second Quarter 2012 Earnings Conference Call - PR Newswire 07.26.12 | 04:07 pm
Partner Headlines for DRRX
- A Study Of 3 Biotechs - A Story Of Hope, Potential And Partnerships - Seeking Alpha 03.18.13 | 09:03 am
- Durect Offers Two Shots On Goal, Almost 100% Upside - Seeking Alpha 02.26.13 | 09:02 am
- 3 Best Biotech Stocks For This Week (Part V) - Seeking Alpha 10.08.12 | 09:10 am
- DRRX - Initiating Coverage of DURECT Corp. - Analyst Blog - NASDAQ 09.11.12 | 02:09 pm
- Benzinga's Microcap Movers for Friday July 20, 2012 - Benzinga 07.21.12 | 05:07 pm
- Pfizer Terminates Development and License Agreement Between Alpharma Ireland and DURECT - Benzinga 03.01.12 | 04:03 pm
- DURECT Announces Top-line Data from BESST; Did Not Reach Statistical Significance - Benzinga 01.05.12 | 04:01 pm
- 12 Healthcare Companies Looking at June Catalysts - Seeking Alpha 05.30.11 | 04:05 am
- Jefferies Reiterates Buy Rating on DURECT Corp. (DRRX) - Benzinga 08.05.10 | 09:08 am
- FDA Clears Hospira's Generic Drug - Analyst Blog - Zacks 06.25.10 | 01:06 pm
